NHS authorities could begin to use the reimbursement system as a “stick” to ensure doctors prescribe cheaper biosimilar medicines amid varied uptake in different regions.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
